T = EV ∧ R = IV ¬ BE (→ absolute BA) [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2020-05-29 19:51 (917 d 04:46 ago) – Posting: # 21492
Views: 840

Hi Ani,

❝ Dear Helmut,

     ▲▲▲▲▲▲ Not interested in opinions of others?


❝ I am interested in finding out if bioequivalence study is needed in the US when an IV formulation is changed to a subcutaneous formulation.


That’s not BE but absolute bioavailability.

❝ I would also appreciate if you can please give me references to US FDA Guidance document that addresses this topic.


Contrary to IV, in SC you have an absorption site. Hence, calling that a “formulation change” is an euphemism. The NDA/IND guidance is a starter.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,424 posts in 4,694 threads, 1,600 registered users;
10 visitors (1 registered, 9 guests [including 6 identified bots]).
Forum time: 23:38 CET (Europe/Vienna)

The rise of biometry in this 20th century,
like that of geometry in the 3rd century before Christ,
seems to mark out one of the great ages or critical periods
in the advance of the human understanding.    R.A. Fisher

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5